A carregar...
Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy
Denosumab, a fully humanised monoclonal antibody, is licensed for treatment of postmenopausal osteoporosis, hormone ablation-induced bone loss and for prevention of skeleton-related events in patients with bone metastases from solid tumours. In pivotal phase 3 randomised trials, denosumab caused pro...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3912364/ https://ncbi.nlm.nih.gov/pubmed/24481018 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2013-202861 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|